Luton, Bedfordshire, United Kingdom, May 18, 2025 (GLOBE NEWSWIRE) -- The global antibody and protein labeling kits market is projected to grow significantly over the next decade, increasing from ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

Columvi combo for relapsed diffuse large B-cell lymphoma faces approval hurdle. Discover implications for U.S. Read more here ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

Discover why Genmab's antibody platforms, growing royalties, and late-stage pipeline make it a top biotech stock for ...

Intranasal foralumab, targets immune cells in the brain to mitigate inflammation, a key contributor to Alzheimer's progression. "I've never seen anything like this, and we've tried a lot of things. So ...

Who doesn’t love a comeback story? Certainly not GSK, which has found a way to resuscitate its cancer treatment Blenrep as a ...

PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the ...